Coming Soon

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy

To study the effect of adding chemotherapy given after breast surgery with aromatase inhibitor and ovarian suppression versus ovarian suppression and endocrine therapy alone, in premenopausal patients with ER-positive, HER2-negative breast cancer.

Age & Gender

18 years ~ 99 years
Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

United States (Nationwide)

Additional Study Information

Principal Investigator

Claire Dees
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)

IRB Number

23-3116

ClinicalTrials.gov

NCT05879926

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.